Jason Hearn, MD

1. Tobalske BW, Hearn JWD, Warrick DR.: Aerodynamics of Intermittent Bounds in Flying Birds Experiments in Fluids 46(5): 963-973, 2009.
2. Hearn JWD, Videtic GMM, Djemil T, Stephans KL.: Salvage Stereotactic Body Radiotherapy (SBRT) for Local Failure after Primary Lung SBRT International Journal of Radiation Oncology, Biology, Physics 90(2): 402-406, 2014. PM25017480
3. Kotecha R, Marwaha G, Hearn JWD, Weller MA, Kupelian P, Reddy CA, Ciezki JP, Stephans K, Tendulkar RD: A Comparison of Long-Term Treatment-Related Toxicities between Moderately Hypofractionated and Conventionally Fractionated Dose-Escalated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology 90(1): 423-424, 2014. (In Press)
4. Spratt D, Jackson W, Abugharib A, Tomlins S, Dess R, Soni P, Lee J, Zhao S, Cole A, Zumsteg Z, Sandler H, Hamstra D, Hearn JWD, Palapattu G, Mehra R, Morgan T, and Feng F: Independent Validation of the Prognostic Capacity of the ISUP Prostate Cancer Grade Grouping System for Radiation Treated Patients with Long-term Follow-up Prostate Cancer and Prostatic Diseases 19(3): 292-7, 2016. PMID 27215611
5. Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang K-H, Carlson R, Rangel L, Reagan R, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, and Sharifi N: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study Lancet Oncology 17(10): 1435-1444, 2016. PMC5135009
6. Dess R, Sun Y, Matuszak M, Sun G, Soni P, Bazza L, Murthy V, Hearn JWD, Kong F, Kalemkerian G, Hayman J, Ten Haken R, Lawrence T, Schipper M, Jolly S.: Cardiac Events after Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small Cell Lung Cancer Journal of Clinical Oncology 35(13): 1395-1402, 2017. PMC5455464
7. Jackson WC, Desai N, Abugharib A,Tumati V, Dess R, Lee J, Zhao Z, Soliman M, Folkert, M, Laine A, Hannan R, Zumsteg Z, Sandler H, Hamstra D, Montgomery J, Miller D, Kozminski M, Hollenbeck B, Hearn JWD, Palapattu G, Tomlins S, Mehra R, Morgan T, Feng F, Spratt D.: Anatomic Patterns of Recurrence Following Biochemical Relapse after Post-Prostatectomy Salvage Radiation Therapy: A Multi- Institutional Study BJU International 120(3): 351-357, 2017. 28139024
8. Hawkins PG, Boonstra PS, Hobson ST, Hearn JWD, Hayman JA, Ten Haken RK, Matuszak MM, Stanton P, Kalemkerian GP, Ramnath N, Lawrence TS, Schipper MJ, Kong (Spring) FM, Jolly S.: Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship Radiotherapy and Oncology 125 (2017): 66-72, 2017. PM28947099/PMCID: 5645039
9. Sun Y, Hawkins PG, Bi N, Tewari M, Hearn JWD, Hayman JA, Kalemkerian GP, Lawrence TS, Ten-Haken RK, Matuszak MM, Kong FM, Jolly S, Schipper MJ: Serum microRNA Signature Predicts Response to High-dose Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer International Journal of Radiation Oncology, Biology, Physics 100(Number 1): 107-114, 2017. PM29051037 /PMC5736451
10. Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumstmeg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE: Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure European Urology. 1(4): 276-282, 2018. PM31100248
11. Hearn JWD, Xie W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M, Kantoff PW, Sharifi N: Association of HSD3B1 Genotype with Response to Androgen-Deprivation Therapy for Biochemical Recurrence after Radiotherapy for Localized Prostate Cancer JAMA Oncol 4(4): 558-562, 2018. PMC5933377
12. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw S, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.: Multi-Institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer European Urology. 2018 Jul; 74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.. (In Press) PMID: 29128208
13. Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.: Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival European Urology [Epub ahead of print]: pii: S0302-2838(17)31070-9. doi:10.1016/j.eururo.2017.12.023, 2018. PMID: 2930651
14. Litzenberg DW, Muenz DG, Archer PG, Jackson WC, Hamstra DA, Hearn JWD, Schipper MJ, Spratt DE: Changes in Prostate Orientation Due to Removal of a Foley Catheter Medical Physics. 45(4): 1369-1378, 2018. PMID 29474748
15. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JWD, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.: Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features JAMA Oncology [Epub ahead of print]: e175230. doi: 10.1001/jamaoncol.2017.5230, 2018. PMID: 29372236
16. Piert M, Shankar PR, Montgomery J, Kunju LP, Rogers V, Siddiqui J, Rajendiran T, Hearn JWD, George A, Shao X, Davenport MS.: Accuracy of tumor segmentation from multi-parametric prostate MRI and 18Fcholine PET/CT for focal prostate cancer therapy applications EJNMMI Res 8(1): 23, 2018. PMC5869349
17. Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE: International Multicenter
    Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy. J Urol 201(2): 284-291, 2019. PM30153435
18. Christensen RE, Nause-Osthoff RC, Waldman JC, Spratt DE, Hearn, JWD: Adverse Events in Radiation Oncology: A Case Series from Wake Up Safe, the Pediatric Anesthesia Quality Improvement Initiative. Paediatr Anaesth 29(3): 265-270, 2019. PM30580487
19. Foster B, Jackson W, Foster C, Dess R, Abu-Isa E, McLaughlin PW, Merrick G, Hearn J, Spratt D, Liauw S, Hamstra D: Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization. Am J Clin Oncol 42(4): 382-390, 2019. PM30724780
20. Paradis KC, Mayo C, Owen D, Spratt DE, Hearn J, Rosen B, Kashani R, Moran J, Tatro DS, Beeler W, Vineberg K, Smith DC, Matuszak MM: The Special Medical Physics Consult Process for Reirradiation Patients. Adv Radiat Oncol 4(4): 559-565, 2019. PM31681862/PMC6817723
21. Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N: Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol:
    JCO1902748, 2019. (In Press) PM31829901
22. Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW , Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT: A
    phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). BMC Cancer 19(1): 572, 2019. PM31196032/PMC6567492
23. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Hearn JWD, Mehra R, Morgan TM, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE.: Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys 104(4): 778-789, 2019. PM30959121/PMC6770993
24. Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, Tewari M, Thomas D, Zhao L, Brown N, Frankel TL, Warren EH, Ramnath N: A Pilot Study of Atezolizumab plus
    Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys: 2019. (In Press) PM31756415
25. Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N: HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol e-published ahead of print: Online, 2020.
    PM32053149
26. Jackson WC, Hartman H, Dess R, Bierer S,Payal S, Hearn JWD, Reichert A, Kishan A, Mahal BA, Zumsteg Z, Efstathiou, Kaffenberger S, Morgan T, Mehar R, Showalter T, Krauss D, Nguyen P, Schipper M, Feng F, Sandler H, Hoskin P, Roach M, Spratt DE: Addition of androgen-deprivation therapy or
    brachytherapy boost to external beam radiotherapy for men with localized prostate cancer: A network meta-analysis of randomized trials Journal Of Clinical Oncology. (In Press)

Book Chapters

1. Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, Tewari M, Thomas D, Zhao L, Brown N, Frankel TL, Warren EH, Ramnath N: A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys: 2019. (In Press) PM31756415
2. Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N: HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol e-published ahead of print: Online, 2020. PM32053149
3. Jackson WC, Hartman H, Dess R, Bierer S,Payal S, Hearn JWD, Reichert A, Kishan A, Mahal BA, Zumsteg Z, Efstathiou, Kaffenberger S, Morgan T, Mehar R, Showalter T, Krauss D, Nguyen P, Schipper M, Feng F, Sandler H, Hoskin P, Roach M, Spratt DE: Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for men with localized prostate cancer: A network meta-analysis of randomized trials Journal Of Clinical Oncology. (In Press)